GeneDx Holdings (WGS) Cost of Revenue (2020 - 2026)

GeneDx Holdings (WGS) has reported Cost of Revenue for 7 consecutive years, with $34.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 18.87% year-over-year to $34.0 million; the TTM figure through Mar 2026 stood at $134.8 million (up 17.52% YoY), while the FY2025 annual figure was $129.4 million, up 16.49% from the prior year.
• Cost of Revenue eased to $34.0 million in Q1 2026 per WGS's latest filing, from $36.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $77.7 million in Q4 2022 and bottomed at $25.0 million in Q1 2024.
• Historically, Cost of Revenue has averaged $38.1 million across 5 years, with a median of $29.9 million in 2023.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 36.51% — and 2023, when it slumped 65.67%.
• GeneDx Holdings' Cost of Revenue stood at $77.7 million in 2022, then plunged by 65.67% to $26.7 million in 2023, then rose by 10.39% to $29.4 million in 2024, then increased by 24.75% to $36.7 million in 2025, then dropped by 7.29% to $34.0 million in 2026.
• Business Quant data shows WGS's Cost of Revenue at $34.0 million in Q1 2026, $36.7 million in Q4 2025, and $32.2 million in Q3 2025.